We protect your health through science
Investigation
Viral Pathogenesis and Immunity
Publications
Where are we with monoclonal antibodies for multidrug-resistant infections?
Where are we with monoclonal antibodies for multidrug-resistant infections? McConnell MJ. Drug Discov Today. 2019 May;24(5):1132-1138. doi: 10.1016/j.drudis.2019.03.002.
PUBMEDPeptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii
Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii. Gil-Marqués ML, Moreno-Martínez P, Costas C, Pachón J, Blázquez J, McConnell MJ. J Antimicrob Chemother. 2018 Nov 1;73(11):2960-2968. doi: 10.1093/jac/dky289.
PUBMEDImmunization with lipopolysaccharide-free outer membrane complexes protects against Acinetobacter baumannii infection
Immunization with lipopolysaccharide-free outer membrane complexes protects against Acinetobacter baumannii infection. Pulido MR, García-Quintanilla M, Pachón J, McConnell MJ. Vaccine. 2018 Jul 5;36(29):4153-4156. doi: 10.1016/j.vaccine.2018.05.113.
PUBMEDPhenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii
Phenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii. Carretero-Ledesma M, García-Quintanilla M, Martín-Peña R, Pulido MR, Pachón J, McConnell MJ. Virulence. 2018 Dec 31;9(1):930-942. doi: 10.1080/21505594.2018.1460187.
PUBMEDCurso de Gestión de Calidad y Buenas Prácticas de Laboratorio. Ed. 3
Grammatico JP, Cuevas L (Edits.) y Grupo de expertos de la Organización Panamericana de la Salud OPS/OMS. Curso de Gestión de Calidad y Buenas Prácticas de Laboratorio. Ed. 3. OPS/OMS;. Washington, D.C., 2016. Disponible en: “http://iris.paho.org/xmlui/handle/123456789/31168”. ISBN: 978-92-75-11906-8
Gestión de la Calidad para laboratorios de ensayo. 1ª ed.
Grammatico JP, Cuevas L (Edits.). Gestión de la Calidad para laboratorios de ensayo. 1ª ed. Conicet-Madri+d; Buenos Aires, 2011. Disponible en: “http://www.madrimasd.org/Laboratorios/Documentos/Red-Laboratorios/documentos/Gest_Calidad_Ensayo.pdf”. ISBN: 978-950-692-095-1
Curso de Gestión de Calidad y Buenas Prácticas de Laboratorio.
Grupo de expertos de la Organización Panamericana de la Salud OPS/OMS. Curso de Gestión de Calidad y Buenas Prácticas de Laboratorio. OPS; Documentos Técnicos THR/HT 2009/001. Washington, D.C., 2009. ISBN: 978-92-75-32977-1
Guía Latinoamericana para la implementación de Código de Ética en los laboratorios de salud.
Grupo de expertos de la Organización Panamericana de la Salud (OPS/OMS). Guía Latinoamericana para la implementación de Código de Ética en los laboratorios de salud. Organización Panamericana de la Salud. Documentos Técnicos. Políticas y Regulación. THS/EV-2007/001; 2007. ISBN: 92-7-532702-5
HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization
Valle-Millares D; Brochado-Kith O; Gómez-Sanz A; et al; Fernández-Rodríguez A (AC). (17/17). 2021. Biomedicine and Pharmacotherapy. Elsevier.
DOIIdentification of HIV-1 circulating BF1 recombinant form (CRF75_BF1) of Brazilian origin that also circulates in Southwestern Europe
Bacqué J, Delgado E, Gil H, Ibarra S, Benito S, García-Arata I, Moreno-Lorenzo M, Sáez de Arana E, Gómez-González C, Sánchez M, Montero V and Thomson MM. Front Microbiol. 2023. 14: 1301374
PUBMED DOIFactors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens.
Gil H, Delgado E, Benito S, Moreno-Lorenzo M, Thomson MM and Spanish Group for the study of antirretroviral drug Resistance. Front Microbiol. 2022. 13:1051096
PUBMED DOITransmission clusters, predominantly associated with men who have sex with men, play a main role in the propagation of HIV-1 in Northern Spain (2013-2018).
Gil H, Delgado E, Benito S, Georgalis L, Montero V, Sánchez M, Cañada-García JE, García-Bodas E, Diaz A, Thomson MM and Spanish group of the study of new HIV diagnoses. Front Microbiol. 2022. 13:782609
PUBMED DOIPotent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses
Beltran-Pavez C, Bontjer I, Gonzalez N, Pernas M, Merino-Mansilla A, Olvera A, Miro JM, Brander C, Alcami J, Sanders RW, Sanchez-Merino V, Yuste E; J Virol. 2022 Jan 12;96(1):e0134321.
PUBMED DOIPermanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure
Casado C, Galvez C, Pernas M, Tarancon-Diez L, Rodriguez C, Sanchez-Merino V, Vera M, Olivares I, De Pablo-Bernal R, Merino-Mansilla A, Del Romero J, Lorenzo-Redondo R, Ruiz-Mateos E, Salgado M, Martinez-Picado J, Lopez-Galindez C; Sci Rep. 2020 Feb 5;10(1):1902
PUBMED DOIGuiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant
Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V; PLoS One. 2018 Dec 19;13(12):e0208345
PUBMED DOIDetection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection
Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C, Ambrosioni J, Schultz A, Meyerhans A, Mascola JR, Gatell JM, Alcami J, Miro JM, Yuste E; J Virol. 2016 May 12;90(11):5231-5245
PUBMED DOIAdditional Information
The activity of this unit focuses on the development and clinical validation of point-of-care diagnostic methodology against liver viruses based on an emerging field, nanotechnology, a line of research that is developed in collaboration with BioAssays SL. Likewise, this unit focuses on delving into the immuno-virological mechanisms underlying viral infections and coinfections with other microorganisms and their influence on the host through a comprehensive approach to laboratory techniques.
One of the main lines of research involves the study of the coinfection of viral hepatitis with the Human Immunodeficiency Virus (HIV), evaluating the impact of coinfection and elimination of hepatitis C on the HIV reservoir, as well as its impact on virus-induced senescence, among others through the use of “omic” technologies.
Our group leads the Multidisciplinary HIV/Hepatitis Coinfection Group (COVIHEP), and maintains collaborations with national and international research groups of excellence, facilitating greater harmonization and quality in the biomedical research carried out. On the other hand, Dr. Briz maintains close collaboration with private companies, promoting intersectoral alliances that represent a competitive advantage.
The activity of this unit focuses on the development and clinical validation of point-of-care diagnostic methodology against liver viruses based on an emerging field, nanotechnology, a line of research that is developed in collaboration with BioAssays SL. Likewise, this unit focuses on delving into the immuno-virological mechanisms underlying viral infections and coinfections with other microorganisms and their influence on the host through a comprehensive approach to laboratory techniques.
One of the main lines of research involves the study of the coinfection of viral hepatitis with the Human Immunodeficiency Virus (HIV), evaluating the impact of coinfection and elimination of hepatitis C on the HIV reservoir, as well as its impact on virus-induced senescence, among others through the use of “omic” technologies.
Our group leads the Multidisciplinary HIV/Hepatitis Coinfection Group (COVIHEP), and maintains collaborations with national and international research groups of excellence, facilitating greater harmonization and quality in the biomedical research carried out. On the other hand, Dr. Briz maintains close collaboration with private companies, promoting intersectoral alliances that represent a competitive advantage.